Business Wire

CORRECTING and REPLACING Veeva Vault PromoMats selected by Roche for Digital Asset Management and Content

Share

The fifth paragraph has been removed from the release.

The corrected release reads:

VEEVA VAULT PROMOMATS SELECTED BY ROCHE FOR DIGITAL ASSET MANAGEMENT AND CONTENT

Vault PromoMats combines digital asset management with medical, legal, regulatory review to streamline content management and distribution

2018 Veeva European Commercial & Medical Summit - Veeva Systems (NYSE:VEEV) today announced that Roche (SWX:ROG) is adopting Veeva Vault PromoMats as their global content and digital asset management (DAM) solution.

“We are proud to partner with Roche on this important initiative to speed time to market of their commercial and medical content,” said John Chinnici, vice president of commercial content at Veeva. “Vault PromoMats gives the life sciences industry a single solution to easily create and distribute content with integrated capabilities to manage rich digital assets.”

Vault PromoMats is the first and only application that combines digital asset management with medical, legal, and regulatory review. Companies can eliminate the need to move, duplicate, and manage content and digital assets across multiple systems for improved visibility, control, and compliance throughout the digital supply chain.

In other news, Veeva introduced Veeva Vault Digital Publishing, a new digital asset management capability in Vault PromoMats and Vault MedComms for brand marketing teams to publish and withdraw approved assets from a central location to any digital channel for faster and easier publishing. Read today’s press release to learn more.

Additional Information

For more on Veeva Vault PromoMats, visit: veeva.com/eu/PromoMats

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veeva_eu on Twitter: twitter.com/veeva_EU

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 675 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2018. This is available on the company’s website at veeva.com/eu under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

Contact information

Roger Villareal
Veeva Systems
+1-
925-264-8885
roger.villareal@veeva.com

Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zyxel Launches 5G NR Fixed Wireless Access Portfolio26.5.2020 09:00:00 EESTPress release

Zyxel Communications announced its 5G Fixed Wireless Access (FWA) product portfolio is available for service providers and mass production will begin as soon as Q2 2020. To accelerate your business with Zyxel 5G NR FWA, click here. Today’s subscribers expect robust bandwidth and low latency. Some households, however, are limited in terms of reliable broadband connections. The Zyxel FWA portfolio helps service providers leverage 5G NR technology to deliver high-capacity, premium broadband services, high-speed connectivity, enhanced network security, and deployment flexibility. With outdoor, indoor, and portable options, Zyxel offers a wide range of products with its 5G NR FWA portfolio, including: · 5G NR Outdoor Router (NR7101) · 5G NR Indoor Router (NR5101) · 5G NR Portable Router (NR2101) Together, these solutions ensure connectivity everywhere. Combining the latest in WiFi 6 technology, Zyxel’s 5G NR solution portfolio creates a superior, ultra-high speed and zero-dead-zone WiFi exp

Kyoto Semiconductor Announces a Photodiode in the Industry’s Smallest Class, with a Broad Range of Sensitivity Wavelengths, from 400 to 1,700 nm26.5.2020 08:00:00 EESTPress release

In the forty years since the company’s founding, Kyoto Semiconductor Co., Ltd., Tsuneo Takahashi, President and CEO, and headquartered in Fushimi Ward, Kyoto, has led the industry with optical solutions built from world-standard technologies and with Japanese quality and attention to production detail. They have announced the development of a Two-Wavelength Photodiode, the KP-2 Two-tone Photodiode KPMC29, in the industry’s smallest class and capable of being surface-mounted, with silicon and indium-gallium-arsenide photodiodes, with photosensitivity for a wide range of wavelengths, from 400 to 1,700 nm, arrayed along the same light axis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005017/en/ Kyoto Semiconductor KP-2 Two-tone Photodiode KPMC29 (Photo: Business Wire) This broadband sensitivity, together with a smaller package that is 1/8 the volume ratio of older Kyoto Semiconductor products, can be used in the health

Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also Announces the Appointment of Three New Board Members25.5.2020 19:30:00 EESTPress release

Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the novel drug candidate (NRD135S.E1) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) to evaluate NRD135S.E1 in a Phase 2 study. Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019. The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months. “Submitting this IND is an important next step in the clinical development of NRD135S.E1 for the treatment of PDPN and we are moving rapidly to potentially address a global unmet medical need,” said Sara Mangialaio, M.D., Ph.D., CMO and Head of R&D at Novarem

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 14:30:00 EESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 11:05:00 EESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 09:00:00 EESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom